Cargando…
A multi-cytokine inhibitory peptide (BNZ 132-1) that is a potential therapeutic agent for HAMTSP and other necrotizing diseases.
Autores principales: | Nata, Toshie, Zapata, Juan Carlos, Massoud, Raya, Jacobson, Steve, Azimi, Nazli, Tagaya, Yutaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577809/ http://dx.doi.org/10.1186/1742-4690-12-S1-O22 |
Ejemplares similares
-
BNZ-gamma peptide, a potential therapeutic agent in HTLV-1 associated myelopathy
por: Massoud, Raya, et al.
Publicado: (2014) -
IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability
por: Wang, T. Tiffany, et al.
Publicado: (2018) -
HBZ RNA may promote cell survival against clastogenic damages and thereby contributes to the development of leukemic ATL cells
por: Goicochea, Marco, et al.
Publicado: (2014) -
Correlation of increased CXCL13 with intrathecal humoral immune responses to HTLV-1 in CSF of patients with HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2014) -
A Review of Approaches to the Metallic and Non-Metallic Synthesis of Benzimidazole (BnZ) and Their Derivatives for Biological Efficacy
por: Patel, Muhammad, et al.
Publicado: (2023)